Intas Biopharmaceuticals

Dong-A ST Demonstrates Therapeutic Equivalence Between DMB-3115 and Stelara in Global Phase III

Retrieved on: 
Tuesday, January 17, 2023
Health, FDA, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, MAT, Ustekinumab, Safety, IQVIA, Psoriasis, Ulcerative colitis, Intas Biopharmaceuticals, Patient, Week, Psoriasis Area and Severity Index, Psoriatic arthritis, III, USD, EMA, Pharmaceutical industry, Vaccine, EU

Dong-A ST (President and CEO: Min-young Kim) (KRX:170900) announced on January 16th that therapeutic equivalence and safety were established between DMB-3115 and Stelara, the reference drug, in global phase III.

Key Points: 
  • Dong-A ST (President and CEO: Min-young Kim) (KRX:170900) announced on January 16th that therapeutic equivalence and safety were established between DMB-3115 and Stelara, the reference drug, in global phase III.
  • DMB-3115 global phase III first kicked off in the US back in 2021 and then in eight European countries, including Poland, Estonia, and Latvia, with a total patient number of 605 over 52 weeks.
  • Patients with moderate to severe chronic plaque psoriasis were treated with DMB-3115 or Stelara PFS to compare efficacy, safety, and immunogenicity.
  • DMB-3115 and Stelara demonstrated therapeutic equivalence when looking at percent change from baseline in PASI (Psoriasis Area and Severity Index) at Week 8 and Week 12.

Accord BioPharma Announces AccordConnects Inventory Management System for Hospitals and Healthcare Practices

Retrieved on: 
Tuesday, January 10, 2023
Computer, Google Play, Software, Hospital, Biology, App store, Intas Biopharmaceuticals, HCPS, Accord, Marketing, Biopharma LLC, Online shopping

DURHAM, N.C., Jan. 10, 2023 /PRNewswire/ -- Accord BioPharma, the U.S. specialty division of Intas Pharmaceuticals, Ltd., focused on development of oncology, immunology, and critical care therapies, today announced the launch of a mobile app and web-based inventory management capability, AccordConnects, which helps healthcare practices track inventory of Accord BioPharma therapies.

Key Points: 
  • DURHAM, N.C., Jan. 10, 2023 /PRNewswire/ -- Accord BioPharma, the U.S. specialty division of Intas Pharmaceuticals, Ltd., focused on development of oncology, immunology, and critical care therapies, today announced the launch of a mobile app and web-based inventory management capability, AccordConnects, which helps healthcare practices track inventory of Accord BioPharma therapies.
  • AccordConnects allows hospitals and healthcare practices to register Accord BioPharma products that they've received in a secure online database, create a link between their Accord BioPharma product inventory and a practice's electronic health record system, view alerts to enable optimal product lifecycle decisions, and keep a record of when inventory has been dispensed.
  • Now, it will provide most of those same capabilities on a website created by Accord BioPharma in addition to—and in concert with—the mobile version.
  • For these reasons, we worked to make our intuitive, user-friendly inventory management system available wherever was most convenient."

Prefilled Syringes Global Market Report 2022: Growing Preference for Self-Injection & Growth of Biologics and Biosimilars Drives Sector - ResearchAndMarkets.com

Retrieved on: 
Monday, December 19, 2022
Medical Supplies, Health, Molecule, World Health Organization, USD, Patient, WHO, Administration, Centers for Disease Control and Prevention, Patent, Chief commercial officer, Syringe, Growth, Element, CPC, COVID-19, Yellow Pills: Prefill, CDC, Glass, Diabetes, Safety, State, Degenerative disease, Prevalence, Machine taper, Stockholm Environment Institute US Center, Cancer, Conditional sentence, Injury, Intas Biopharmaceuticals, Research, Hospital, Fine chemical, Pharmaceutical industry, Medical device, Injection moulding, Generic drug, Risk management, Video game console, Borosilicate glass, Management, Beer

This report features an extensive study of the current market landscape and the likely future potential associated with the prefilled syringe market, over the next decade.

Key Points: 
  • This report features an extensive study of the current market landscape and the likely future potential associated with the prefilled syringe market, over the next decade.
  • We believe that the aforementioned developments are likely to fuel the ongoing innovation and growth of the prefilled syringes market in the foreseen future.
  • What are the crucial factors that are driving the prefilled syringes market?
  • How is the current and future market opportunity likely to be distributed across key market segments?

Accord Healthcare Adds Generic Drug for Use in Treating Leukemia and Non-Hodgkin's Lymphoma

Retrieved on: 
Wednesday, December 7, 2022
CLL, Heart, Food, Rash, Teva, Cough, NHL, Patient, Diarrhea, Chronic lymphocytic leukemia, Research, Food and Drug Administration, Nausea, Aplastic anemia, Headache, United States National Library of Medicine, Fatigue, FDA, Vomiting, Injection, Breathe Me, US Foods, MedlinePlus, Pharmacist, Anaphylaxis, Growth, Constipation, AP, Safety, Purging disorder, Accord, National library, Infection, Tumor lysis syndrome, Rituximab, Intas Biopharmaceuticals, MEDLINE, Pharmaceutical industry, Fever, Bendamustine

DURHAM, N.C., Dec. 7, 2022 /PRNewswire/ -- Accord Healthcare, Inc., a leading generic pharmaceutical company, has added Bendamustine Lyo. Injection to its line of chemotherapy drugs. Accord's product is AP rated to Teva's Treanda® and is being offered in both 25-mg and 100-mg vials.

Key Points: 
  • DURHAM, N.C., Dec. 7, 2022 /PRNewswire/ -- Accord Healthcare, Inc. , a leading generic pharmaceutical company, has added Bendamustine Lyo.
  • Accord Healthcare, a wholly owned subsidiary of Intas Pharmaceuticals, is a leading generic pharmaceutical company.
  • Accord Healthcare combines its advanced manufacturing technology with in-house research to produce highly complex, affordable, and essential medicines.
  • Accord Healthcare's forward-thinking, innovative approach, and its resolve to help patients remains at the heart of everything they do.

Accord BioPharma Partners with StoryMD to Deliver Advanced Prostate Cancer Educational Content to Clinicians and Patients

Retrieved on: 
Tuesday, September 20, 2022
Intas Biopharmaceuticals, Spinal cord compression, Electrolyte, Time, Extremities, Efficiency, Risk, Convulsion, Food, Association, Knowledge, Hypersensitivity, Hyperglycemia, Partnership, Gonadotropin-releasing hormone, NDA, Urinary tract obstruction, Stroke, Hypertension, QT, Critical care, Patient, Pregnancy, Severe cutaneous adverse reactions, Lists of diseases, Regulation of tobacco by the U.S. Food and Drug Administration, Accord, Physician, CEO, Leuprorelin, Technology, Paralysis, Pain, Biology, Serum, Cardiovascular disease, Drug development, Caregiver, New Drug Application, Anaphylaxis, Testosterone, Myocardial infarction, Prostate cancer, Medicine, Awareness, Man, Fatigue, Multimedia, Communication, Education, Disease, Cancer, Medical imaging, Pharmaceutical industry, Vaccine

Accord BioPharma has signed on as StoryMD's very first corporate partner, to support StoryMD's advanced prostate cancer content , allowing Accord BioPharma to provide a comprehensive, user-friendly tool to help patients and their caregivers navigate advanced prostate cancer, just in time for prostate cancer awareness month thisSeptember.

Key Points: 
  • Accord BioPharma has signed on as StoryMD's very first corporate partner, to support StoryMD's advanced prostate cancer content , allowing Accord BioPharma to provide a comprehensive, user-friendly tool to help patients and their caregivers navigate advanced prostate cancer, just in time for prostate cancer awareness month thisSeptember.
  • "StoryMD exemplifies that mission by providing clinicians with clear, easy-to-understand visuals, videos, and health information that help their patients understand their disease journey.
  • Partnering with StoryMD on their advanced prostate cancer content felt like a natural fit given our recent drug launch."
  • In March of this year, Accord BioPharma announced the U.S. launch of CAMCEVI (leuprolide) 42mg injection emulsion for the treatment of advanced prostate cancer in adults.

Accord Healthcare Adds Pemetrexed Injection to Generic Chemotherapy Drug Portfolio

Retrieved on: 
Tuesday, September 13, 2022
Intas Biopharmaceuticals, Malignancy, Incidence, Mesothelioma, Ageing, Pemetrexed, Chest pain, Blistering, FDA, Solution, NSCLC, Vomiting, Population, MPM, Product, Lung cancer, Patient, Accord, Cancer, Technology, Heart, Research, Nausea, Fatigue, Chemotherapy, Pharmaceutical industry

DURHAM, N.C., Sept. 13, 2022 /PRNewswire/ -- Accord Healthcare, Inc., a leading generic pharmaceutical company, has added Pemetrexed Injection (Solution) to its line of chemotherapy drugs. The new drug is formulated as a single-dose vial in 25-mg/ml concentrate for solution for infusion.

Key Points: 
  • DURHAM, N.C., Sept. 13, 2022 /PRNewswire/ --Accord Healthcare, Inc., a leading generic pharmaceutical company, has added Pemetrexed Injection (Solution) to its line of chemotherapy drugs.
  • The new drug is formulated as a single-dose vial in 25-mg/ml concentrate for solution for infusion.
  • Accord Healthcare, a wholly owned subsidiary of Intas Pharmaceuticals, is a leading generic pharmaceutical company.
  • Accord Healthcare combines its advanced manufacturing technology with in-house research to produce highly complex, affordable, and essential medicines.

Accord Healthcare Launches Generic Drug for Treating Brain Tumors & Blood Cancers

Retrieved on: 
Tuesday, August 23, 2022
Intas Biopharmaceuticals, Glioblastoma, Technology, Safety, Research, Carmustine, Disease, Solution, Multiple myeloma, Heart, Liver, Skin, Headache, Hodgkin lymphoma, Lymphatic system, Brain, Astrocytoma, Product, FDA, Vomiting, Bone marrow, Institution, Growth, Urine, Nausea, Patient, Medulloblastoma, Pharmaceutical industry, Accord

DURHAM, N.C., Aug. 23, 2022 /PRNewswire/ -- Accord Healthcare, Inc., a leading generic pharmaceutical company, has added Carmustine to its line of chemotherapy drugs. The drug is formulated as a sterile lyophilized (freeze-dried) powder to be reconstituted for intravenous infusion. Carmustine is therapeutically equivalent to Avet Pharmaceuticals Inc.'s BiCNUR and approved for use in the treatment of certain types of brain tumors and blood cancers. Accord is offering Carmustine in a 50-mg size, as well as the new, larger 300-mg strength, which was not previously available in the market and overcomes the potential need to use multiple vials of the smaller size.

Key Points: 
  • DURHAM, N.C., Aug. 23, 2022 /PRNewswire/ -- Accord Healthcare, Inc., a leading generic pharmaceutical company, has added Carmustine to its line of chemotherapy drugs.
  • "Adding this chemotherapy drug to our portfolio illustrates Accord's commitment in the US market to support healthcare providers in prescribing accessible oncology medications."
  • Further information about safety and potential side effects can be found on the Products page at Accord Healthcare US.
  • Accord Healthcare, a wholly owned subsidiary of Intas Pharmaceuticals, is a leading generic pharmaceutical company.

Comera Life Sciences Provides Business Highlights and Reports Financial Results for the Second Quarter 2022

Retrieved on: 
Wednesday, August 10, 2022
Intellectual property, Excipient, Sumathi Best Television Current Reporting Award, CMRA, Filtration, Risk, Industry, Accounting, GLOBE, Forward-looking statement, Mab, Immune system, Technology, Growth, SEC, Toxicity, Absorption, Patent, Caffeine, Research, Nasdaq, Patient, Company, COVID-19, Acquisition, Partnership, Safety, SPAC, Campbell, Melanoma, Freedom, Animal, Ipilimumab, Intas Biopharmaceuticals, Medicine, Efficiency, Pharmaceutical industry, Cryptocurrency

WOBURN, Mass., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA), a life sciences company developing a new generation of bio-innovative biologic medicines to improve patient access, safety, and convenience, today provided a business update and reported financial results for the quarter ended June 30, 2022.

Key Points: 
  • WOBURN, Mass., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA), a life sciences company developing a new generation of bio-innovative biologic medicines to improve patient access, safety, and convenience, today provided a business update and reported financial results for the quarter ended June 30, 2022.
  • In May 2022, Comera Life Sciences, Inc. completed its business combination with OTR Acquisition Corp. , a publicly traded special purpose acquisition company (SPAC).Comera began trading on the Nasdaq Capital Market under the symbol CMRA onMay 20, 2022.
  • In June 2022, Comera appointed Michael Campbellas Executive Vice President and Chief Financial Officer.
  • To learn more about the Comera Life Sciences mission, as well as the proprietary SQore platform, visit https://comeralifesciences.com/ .

Prestige Biopharma and Intas Pharmaceuticals Announce Partnership to Commercialize Bevacizumab Biosimilar in the US, Europe, Canada, MENA, Brazil, Mexico, South Africa, CIS and the SEA countries

Retrieved on: 
Tuesday, July 26, 2022
Biotechnology, General Health, Health, Pharmaceutical, Oncology, Antibody, Intas Biopharmaceuticals, Mab, Trastuzumab, API, CEO, Pancreatic cancer, EMA, Partnership, Marketing, USD, Bevacizumab, COVID-19, Safety, Cancer, Accord, VEGF, Technology, FDA, Phase 1, Patient, Pharmacokinetics, KRX, Adalimumab, INN, Prestige, MFDS, MENA, Vaccine, Pharmaceutical industry, Fine chemical, EU

HD204 is currently in Phase III clinical development (SAMSON-II) and the US and EU filing is planned next year.

Key Points: 
  • HD204 is currently in Phase III clinical development (SAMSON-II) and the US and EU filing is planned next year.
  • Positive results were previously reported from the Phase I clinical trial (SAMSON-I) which evaluated the pharmacokinetics, safety and immunogenicity of HD204 to Avastin.
  • Lisa S. Park, CEO of Prestige Biopharma, commented: We are delighted to establish a partnership with Intas for the key markets, the US and Europe.
  • Binish Chudgar, Vice Chairman & Managing Director of Intas Pharmaceuticals, commented: We are pleased to announce the collaboration with Prestige Biopharma.

G-CSF (Granulocyte Colony Stimulating Factors) Global Market Research Report 2022 - ResearchAndMarkets.com

Retrieved on: 
Thursday, June 30, 2022
Health, Pharmaceutical, Death, G-CSF, Granulocyte colony-stimulating factor, Teva Pharmaceuticals, Bone marrow, Sepsis, Patient, G-CSF factor stem-loop destabilising element, Pegfilgrastim, Lenograstim, Breast cancer, Laboratory, Population growth, Infection, Growth, IARC, Celltrion, Application, American Journal, Mortality, Febrile neutropenia, Prevalence, PPG, Disorder, The American Journal of Managed Care, Risk, Growth hormone, International Agency for Research on Cancer, Organic, Intas Biopharmaceuticals, Novartis, Neutropenia, Filgrastim, Amgen, Medicare, Degenerative disease, Research, FN, Demography, Vaccine, Dietary supplement, Pharmaceutical industry, Lithium, Cancer, Pfizer

The "G-CSF (Granulocyte Colony Stimulating Factors) Global Market Report 2022: By Type, By Application, By Product" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "G-CSF (Granulocyte Colony Stimulating Factors) Global Market Report 2022: By Type, By Application, By Product" report has been added to ResearchAndMarkets.com's offering.
  • The G-CSF (Granolocyte Colony Stimulating Factors) market global report answers all these questions and many more.
  • Global G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
    Long acting (pegylated) filgrastim (pegfilgrastim, Neulasta, Pelmeg, Ziextenco)
    6.2.
  • Global G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion